author-photo

Gopinath Ganji

GlaxoSmithKline

14

Papers

2004

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers

2018 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (84)
A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (69)
792PDPhase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K)β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230

2016 Oncotarget
Show All
- Source
- Cite
- Save
Citations (25)
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

2013 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (140)
Méthodes de traitement du cancer

2012
Show All
- Source
- Cite
- Save
Citations (0)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

2012 Nature
Show All
- Source
- Cite
- Save
Citations (1283)
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

2012 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (343)
Abstract #LB-256: Enzastaurin inhibits in vivo GSK3\#946; phosphorylation in early breast cancer

2009 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)